IL-6, as a biomarker for the prognosis and treatment response of COVID-19 patients, has been extensively studied and applied in clinical practice (3, 4); however, the measurement of individual cytokine levels alone cannot fully reflect the immune status of patients. Here, IL6 is linked to COVID-19.